‘The rapid progress in this collaboration demonstrates Anchor’s ability to discover promising brand-new pepducin therapeutic compounds. Our use OMJPI has been incredibly efficient and cooperative together,’ said Frederick Jones, M.D., President and CEO of Anchor.. Anchor announces rapid progress in OMJPI collaboration for developing GPCR therapeutic compounds Anchor Therapeutics today announced that it offers successfully completed the 1st stage of its collaboration and license agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. . This accomplishment represents rapid progress for the collaboration, that was released in September 2010 to build up G protein coupled receptor -targeted therapeutic compounds making use of Anchor’s proprietary pepducin technology.6 election as proof that Americans support raising taxes instead of cutting spending. ‘With regards to Social Security, Medicaid and Medicare, the American people informed us to safeguard and strengthen these applications, not cut them,’ Harkin stated . This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research company unaffiliated with Kaiser Permanente. Nearly 100 percent of people between your age range of twelve and seventeen possess at least occasional breakouts of whiteheads, blackheads or a pimple, and then now. Natural treatment options are always an improved choice for acne because of less contact with drugs and chemical-laden pimples products.